Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abcam, Avacta, Applied Spectral Imaging, Biotome, Brainchip, Critical Transport Solutions Australia, Cryoport, Eurofins Viacor, Heartflow, Kromatid, Masimo, Motus GI, Novel Microdevices, Oncimmune, Ortho Regenerative Technologies, Roche.
New hires and promotions in the med-tech industry, including: Biomagnetic Sciences, Cardiac Dimensions, Dascena, Intersect ENT, Second Sight Medical, Vivasure.
Keeping you up to date on recent developments in oncology, including: Popcorn-like gold nanofilms for detection of miRNA in cancer; Myeloid cells differ in primary and recurrent glioblastoma; Premetastatic niche is prepared via leaky gut in colorectal cancer; Brain metastases of breast cancer depend on fatty acid synthesis.
Nearly 16,500 groups and individuals put in their two cents on a proposed National Institute of Standards and Technology (NIST) rule clarifying that the U.S. government, under the Bayh-Dole Act, can’t march in on patents derived from federally funded research just because it doesn’t consider the price of the resulting product “reasonable.”
The European Commission opened a public consultation to help it develop the Health Emergency Preparedness and Response Authority, a new initiative to better prepare Europe for cross-border health threats.
The FDA has granted 510(k) clearance to Orthofix Medical Inc.’s Construx Mini Ti spacer system for anterior cervical discectomy and fusion (ACDF) procedures. Company documents claim the implant has an optimized porosity and pore size, which creates a 3D porous surface with the potential for bone ingrowth.
Nevro Corp.'s spinal cord stimulation system cut diabetic neuropathy pain in half or more in 85% of patients in a study published on April 5 in JAMA Neurology. Patients receiving the stimulation treatment delivered by the Senza system experienced an average reduction in pain of 76% at six months in the largest clinical largest trial to date to evaluate the use of spinal cord stimulation (SCS) in painful diabetic neuropathy (PDN).
Invitae Corp. has inked a definitive agreement to acquire Genosity Inc., a genomics company with a technology platform for next-generation sequencing (NGS) assays, for approximately $200 million in cash and stock. Separately, the medical genetic testing company reported a $1.15 billion investment, led by Softbank Group subsidiary SB Management, to support ongoing growth initiatives. San Francisco-based Invitae expects the Genosity platform to accelerate the development and launch of its oncology products, including three tests that won FDA breakthrough device designation.
RSS
